e-learning
resources
Munich 2006
Tuesday 05.09.2006
Lung transplantation: infection, rejection, animal models and more
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum CA 19-9 in lung allograft recpients
I. A. Forrest, C. Ward, D. M. Murphy, G. E. Johnson, P. A. Corris (Newcastle upon Tyne, United Kingdom)
Source:
Annual Congress 2006 - Lung transplantation: infection, rejection, animal models and more
Session:
Lung transplantation: infection, rejection, animal models and more
Session type:
Poster Discussion
Number:
4466
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. A. Forrest, C. Ward, D. M. Murphy, G. E. Johnson, P. A. Corris (Newcastle upon Tyne, United Kingdom). Serum CA 19-9 in lung allograft recpients. Eur Respir J 2006; 28: Suppl. 50, 4466
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
The impact of anti-IgE treatment on the airway microbiome in asthma.
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Related content which might interest you:
Ca 19-9 serum levels in patients with end-stage Idiopathic Pulmonary Fibrosis (IPF)
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018
KL-6 in serum as a biomarker for differentiation of chronic allograft dysfuntion in lung transplant. Preliminary results
Source: International Congress 2016 – Post-transplant complications: from animal models to the bedside
Year: 2016
Lung transplantation of ventilator-dependent patients - analysis of survival and graft function in 27 patients
Source: Eur Respir J 2001; 18: Suppl. 33, 179s
Year: 2001
Pretransplant factors influencing survival in cystic fibrosis (CF) patients after lung transplantation (LTx)
Source: Eur Respir J 2006; 28: Suppl. 50, 724s
Year: 2006
Intraabdominal sequestration of the lung and elevated serum levels of CA 19-9: a diagnostic pitfall
Source: Eur Respir J 2004; 24: Suppl. 48, 533s
Year: 2004
Covid 19 in a lung transplant population
Source: Virtual Congress 2021 – Challenging problems in lung transplantation
Year: 2021
II-17 upregulation in BAL-fluid during acute rejection after lung transplantation: a 3 months follow-up
Source: Eur Respir J 2004; 24: Suppl. 48, 180s
Year: 2004
Serum cytokines patterns in lung transplant recipients
Source: International Congress 2015 – Pathogenic mechanisms of lung transplant complications: a focus on CLAD
Year: 2015
Antibodies against
P. aeruginosa
exoproteases in BAL from lung transplant recipients
Source: Annual Congress 2010 - New clinical and experimental insights in lung transplantation
Year: 2010
Elevated lung clearance index (LCI) as an early marker of future bronchiolitis obliterans (BOS) post lung transplant
Source: Virtual Congress 2020 – Treatments and biomarkers for lung allograft function and outcome
Year: 2020
Bronchial epithelial cell B7-1 and B7-2 mRNA expression after lung transplantation: a role in allograft rejection?
Source: Eur Respir J 2002; 20: 165-169
Year: 2002
Elevation of serum tumor markers in patients with interstitial lung disease
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011
The diaphragm before and after lung transplant (LT)
Source: International Congress 2018 – Moving lung transplantation forward
Year: 2018
Breath VOC patterns of lung transplant recipients with and without chronic lung allograft dysfunction (CLAD)
Source: International Congress 2017 – Chronic airway disease: markers of disease impact
Year: 2017
Exercise capacity in patients with cystic fibrosis at 6 and 12 months after lung transplantation
Source: International Congress 2018 – Latest developments in cystic fibrosis
Year: 2018
Azithromycin (Azi) treatment for chronic allograft dysfunction after lung transplantation (LTx)
Source: Annual Congress 2003 - Bronchiolitis obliterans: diagnosis and treatment
Year: 2003
Late-breaking abstract: Non specific IgG replacement in lung transplantation recipients with low IgG plasma levels: Effects on survival and bronchiolitis obliterans syndrome occurrence
Source: Annual Congress 2011 - Immunobiology in the transplanted lung: experimental and clinical evaluations
Year: 2011
Survival and lung function in double lung transplant recipients with cystic fibrosis
Source: International Congress 2017 – From donor lung selection and organ preservation to lung transplant outcome
Year: 2017
12 month follow-up of lung recipients with chronic allograft dysfunction treated with extracorporeal photopheresis (ECP)
Source: Annual Congress 2011 - Improving outcomes after lung transplantation
Year: 2011
Serum levels of thrombopoietin (TPO) in patients with thrombocytosis due to lung cancer and in essential throbocythaemia (ET)
Source: Eur Respir J 2001; 18: Suppl. 33, 234s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept